NasdaqGS:HTZ
NasdaqGS:HTZTransportation

Is Bill Ackman’s Bullish Spotlight on Hertz (HTZ) Reframing Its High-Risk Turnaround Narrative?

Earlier this week, prominent investor Bill Ackman highlighted a bullish analysis of Hertz Global Holdings on social media, drawing fresh attention to the car rental group’s turnaround story despite its ongoing financial strains. A particularly interesting aspect of this episode is how a single high-profile endorsement reshaped investor focus on Hertz’s long-term prospects, even as conventional metrics still flag elevated risk. Next, we’ll examine how Ackman’s public endorsement intersects...
NasdaqGS:QLYS
NasdaqGS:QLYSSoftware

Assessing Qualys (QLYS) Valuation After Recent Sideways Trading and Cooling Momentum

Qualys (QLYS) has been drifting sideways lately, but the stock’s mixed near term performance contrasts with its steadier multi year gains. This raises a simple question for investors: is this consolidation offering reasonable value? See our latest analysis for Qualys. Over the past year Qualys has seen modest 90 day share price gains alongside a slightly negative 1 year total shareholder return. This suggests momentum has cooled a bit as investors reassess growth versus valuation after a...
NasdaqGS:GOOGL
NasdaqGS:GOOGLInteractive Media and Services

Has Alphabet’s 66% 2025 Rally Already Priced In Its AI and Cloud Ambitions?

If you are wondering whether Alphabet at around $314 a share is still a smart buy after its massive run, you are not alone. That is exactly what this breakdown is here to tackle. The stock has climbed 5.9% over the last week but is roughly flat over the last month, while still showing longer term gains of 65.8% year to date and 60.8% over the past year that keep expectations high. Those moves sit against a backdrop of Alphabet investing heavily in AI infrastructure and cloud services,...
NYSE:CLVT
NYSE:CLVTProfessional Services

Clarivate (CLVT) Valuation Revisited After Morgan Stanley Downgrade and Ongoing Turnaround Concerns

Morgan Stanley’s downgrade of Clarivate (CLVT) to Underweight puts a sharper spotlight on the company’s slow moving turnaround, rising AI driven competition, and tightening budgets across key customer groups that rely on its data platforms. See our latest analysis for Clarivate. The downgrade lands after a tough stretch for shareholders, with the share price at $3.41 and a year to date share price return of around negative 34 percent. The five year total shareholder return of roughly negative...
NasdaqGS:BSY
NasdaqGS:BSYSoftware

How Investors Are Reacting To Bentley Systems (BSY) Softer Billings And Rising Competitive Pressure

In recent months, Bentley Systems reported softer billings that point to subdued demand and intensifying competition in its infrastructure software markets. This slowdown raises questions about how much newer products and services can contribute to accelerating growth, despite earlier optimism around AI-driven initiatives. Next, we’ll examine how weaker billings and rising competitive pressure may influence Bentley Systems’ broader investment narrative and future expectations. Explore 28 top...
NasdaqGS:FFIV
NasdaqGS:FFIVCommunications

How Alleged Concealment of a Major BIG-IP Cyber Breach At F5 (FFIV) Has Changed Its Investment Story

In the past year, multiple law firms, including Levi & Korsinsky and Rosen Law Firm, have launched securities class actions alleging F5 misled investors about a significant cybersecurity breach affecting its BIG-IP product and the company’s security capabilities. The lawsuits center on claims that F5’s delayed and incomplete disclosure of a nation-state attack and its impact on growth expectations left investors unaware of the risks tied to the company’s highest-revenue offering. We’ll now...
NasdaqCM:VKTX
NasdaqCM:VKTXBiotechs

Viking Therapeutics (VKTX): Revisiting Valuation After a Renewed Share Price Rally

Viking Therapeutics (VKTX) has been on traders radar after its recent share price climb, and the move is forcing investors to revisit what is actually priced into this clinical stage pipeline. See our latest analysis for Viking Therapeutics. The latest leg higher has pushed Viking Therapeutics to a share price of $37.35, capping a powerful 90 day share price return of nearly 49 percent even though the year to date share price return is still negative and the one year total shareholder return...
NasdaqGS:STLD
NasdaqGS:STLDMetals and Mining

Steel Dynamics (STLD): Assessing Valuation After a Strong 3-Month Share Price Run-Up

Steel Dynamics (STLD) has quietly rewarded patient shareholders, with the stock up around 29% over the past 3 months and more than 52% over the past year, outpacing many industrial peers. See our latest analysis for Steel Dynamics. That run up has been driven more by a steady re rating of expectations than any single headline, with the latest 30 day share price return of about 9% extending a strong multi year total shareholder return trend and indicating that momentum is still building. If...
NYSE:DK
NYSE:DKOil and Gas

Delek US Holdings (DK): Valuation Check After a 22% Pullback from Recent Highs

Stock performance and recent moves Delek US Holdings (DK) has quietly pulled back over the past month, dropping roughly 22%, even though its year to date return remains strong. That combination of recent weakness and longer term strength makes the latest slide worth a closer look. See our latest analysis for Delek US Holdings. With the latest share price at $29.71, Delek US Holdings has seen near term share price momentum cool after a strong year to date share price return and robust one year...